Trial Profile
A Phase 1 Dose-Escalation Study of Intraperitoneal (IP) Cisplatin, IV/IP Paclitaxel, IV Bevacizumab, and Oral Olaparib for Newly Diagnosed Ovarian, Primary Peritoneal, and Fallopian Tube Cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Olaparib (Primary) ; Cisplatin; Paclitaxel; Paclitaxel
- Indications Adenocarcinoma; Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer; Sarcoma
- Focus Adverse reactions
- 20 Aug 2020 Status changed from active, no longer recruiting to completed.
- 15 May 2020 Planned End Date changed from 1 Apr 2020 to 1 Apr 2021.
- 15 May 2020 Planned primary completion date changed from 1 Apr 2020 to 1 Apr 2021.